antibody-drug conjugates
| 3 min read
Starting from a defined mechanism can cause discovery programs to miss the best drug candidates.
| 5 min read
New conjugation chemistries are giving developers greater control over targeting, stability, and payload release.
Explore how charge variant fractionation combined with downstream analysis methods can reveal molecular differences in complex biotherapeutics.
| 2 min read
A new alternative approach to antibody-drug conjugates takes advantage of cancer cells’ need for fuel — first by encouraging them to overdose on glucose and then by blocking its backup source of fat.
| 4 min read
FDA approvals, pharma deals, and more led the news this week.
Available on Demand
Learn how to detect aggregation early and quantify proteins, peptides, and ADCs fast with combined UV/Vis and DLS in one low-volume, automated workflow.
| 4 min read
Marriage linked to lower cancer risk, pharma deals, and more led the news this week.
| 4 min read
Greater focus on non-animal testing methods in the UK, a new CRISPR treatment to lower cholesterol, and positive results for a BTK inhibitor in MS led the news this week.
| 4 min read
FDA approvals, rejections, antibody-drug conjugate deals, and more led the news this week.
| 2 min read
New funding will support scaling, team expansion, and the launch of customizable solutions for spatial biology, proteomics, and single-cell analysis.
